John Gnann to Cytomegalovirus Retinitis
This is a "connection" page, showing publications John Gnann has written about Cytomegalovirus Retinitis.
Connection Strength
0.061
-
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11.
Score: 0.061